Key Takeaways
- • Ben Luckett, managing director of venture and strategic capital at Aviva, set up the insurer's venture capital platform in July 2015 and has led it since then.
- • Aviva's venture arm is positioning its UK-focused innovation strategy as a core part of its investment approach, according to a Venture Capital Journal interview published 21 October 2025.
- • The interview, conducted by Joe Marsh, is part of PEI's LP Insight series profiling limited partners.
Summary
Venture Capital Journal interviewed Ben Luckett, managing director of venture and strategic capital at Aviva, about the insurer's venture capital platform and its focus on UK innovation. According to the report, Luckett established Aviva's VC platform in July 2015 and has led it in the decade since as managing director of venture and strategic capital.
The article, written by Joe Marsh and published on 21 October 2025 by PEI Private Equity under its LP Insight profile series, examines why Aviva is directing its venture activity toward UK-based innovation. The source material available for this summary is limited to the article's headline, byline, publication details and an introductory synopsis, so specific fund sizes, portfolio companies, deal values and detailed investment rationale cannot be confirmed from the text provided.
For institutional investors and allocators, the piece offers a view into how a large UK insurer structures and resources a corporate venture program as a long-term strategic allocation. Readers seeking the specific investment thesis, target sectors and performance details should refer to the full Venture Capital Journal interview.
The article, written by Joe Marsh and published on 21 October 2025 by PEI Private Equity under its LP Insight profile series, examines why Aviva is directing its venture activity toward UK-based innovation. The source material available for this summary is limited to the article's headline, byline, publication details and an introductory synopsis, so specific fund sizes, portfolio companies, deal values and detailed investment rationale cannot be confirmed from the text provided.
For institutional investors and allocators, the piece offers a view into how a large UK insurer structures and resources a corporate venture program as a long-term strategic allocation. Readers seeking the specific investment thesis, target sectors and performance details should refer to the full Venture Capital Journal interview.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.